Mark L. Perry
Mr. Perry has served as a member of GBT’s board of directors since April 2015. He has extensive experience serving in professional and management positions in the biotechnology industry. Previously, he served as an entrepreneur-in-residence at Third Rock Ventures, a venture capital firm. Currently, he serves on various boards of companies and nonprofit organizations. Previously, he was president and chief executive officer of Aerovance, a biotechnology company. Prior to that, he was the senior business advisor for Gilead Sciences, Inc., and was an executive officer during which time he served in a variety of capacities, including general counsel, chief financial officer and executive vice president of operations. Earlier in his career, he served as an attorney and partner at Cooley LLP. Mr. Perry currently serves on the boards of directors of NVIDIA Corporation and MyoKardia, Inc. He received a B.A. in history from the University of California, Berkeley, and a J.D. from the University of California, Davis.